Cancer immunotherapy

Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation

Retrieved on: 
Thursday, December 2, 2021
Synthase, Data analysis, Company, Database, Legislation, EST, GLOBE, Immune system, Infection, Cell cycle, COVID, TMB-2, Pressure, School, Time, Brain, Lymphocyte, Cancer, Alzheimer's disease, TBIA, Research, Method, Coronavirus, Solution, U.S. Securities and Exchange Commission, OTCQB, Airport, Apoptosis, Patient, Neuron, Technology, Industry, Monocyte, MERS, Plasma, PCR, Neurodegeneration, Computer, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, COVID-19, Quarantine, Knowledge, Pharmaceutical industry, Vaccine, Medical imaging

Dr. Arad is a pioneer in the discovery and development of 3CL protease biology related products and product candidates.

Key Points: 
  • Dr. Arad is a pioneer in the discovery and development of 3CL protease biology related products and product candidates.
  • Dr. Dorit Arad is an interdisciplinary scientist with expertise in Computer assisted Drug Design, Biotechnology, mechanism-based drug design, Diagnostics, infectious disease and cancer.
  • Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.
  • Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19.

Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma

Retrieved on: 
Tuesday, November 30, 2021
Synthase, Biology, Doctor of Philosophy, Legislation, GLOBE, Dietary supplement, NLC, Immune system, SPAC, Drug development, Infection, Cell cycle, COVID, IP, CEO, TMB-2, Pressure, School, Time, Brain, Lymphocyte, Cancer, Alzheimer's disease, TBIA, Research, Science, Social media, TEL, T cell, Method, Coronavirus, IPO, Solution, Therapy, Vaccine, U.S. Securities and Exchange Commission, Omicron, OTCQB, Airport, Apoptosis, Patient, Neuron, Technology, Industry, Monocyte, Acquisition, MERS, Plasma, PCR, Neurodegeneration, Computer, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, COVID-19, Quarantine, Knowledge, NEW, Pharmaceutical industry, Medical imaging

We believe this acquisition will solidify Todos Medicals position as a key player in the development and commercialization of 3CL protease-related products.

Key Points: 
  • We believe this acquisition will solidify Todos Medicals position as a key player in the development and commercialization of 3CL protease-related products.
  • Under the terms of the agreement, Todos Medical will own 60% of 3CL Sciences, and the shareholders of NLC Pharma will own 40% upon the execution of definitive agreements (the Closing) to acquire all intellectual property and assets related to 3CL protease biology-related products to which NLC Pharma has rights.
  • Todos Medical will assign its European licensing agreement T-Cell Hellas Protect S.A. to 3CL Sciences.
  • Tollovid's 3CL protease inhibition activity release criteria is at least twice as stringent as Tollovid Daily's 3CL protease inhibition release criteria.

Data on Naptumomab Estafenatox (NAP) Enhancing CAR-T cells Potency Presented by NeoTX at SITC 2021 Annual Meeting

Retrieved on: 
Tuesday, November 30, 2021
Patient, Large-cell lung carcinoma, Cancer immunotherapy, Walter, Annual general meeting, Society, Society for Immunotherapy of Cancer, Neoplasm, TTS, Washington Convention Center, Poster, NAP, Therapy, SITC, Immunotherapy, Walter E. Washington Convention Center, Vaccine

NeoTX presented data that shows that NAP generates more potent CAR-T cells and acts synergistically against tumor cell lines in vitro.

Key Points: 
  • NeoTX presented data that shows that NAP generates more potent CAR-T cells and acts synergistically against tumor cell lines in vitro.
  • To access the presented poster, please click here .
  • NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform.
  • The company's lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for non-small cell lung cancer and other solid tumors.

Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma

Retrieved on: 
Monday, November 29, 2021
Synthase, Biology, Doctor of Philosophy, Legislation, GLOBE, Dietary supplement, NLC, Immune system, SPAC, Drug development, Infection, Cell cycle, COVID, IP, CEO, TMB-2, Pressure, School, Time, Brain, Lymphocyte, Cancer, Alzheimer's disease, TBIA, Research, Science, Social media, T cell, Method, Coronavirus, IPO, Solution, Therapy, Vaccine, U.S. Securities and Exchange Commission, Omicron, OTCQB, Airport, Apoptosis, Patient, Neuron, Technology, Industry, Monocyte, Acquisition, MERS, Plasma, PCR, Neurodegeneration, Computer, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, COVID-19, Quarantine, Knowledge, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has entered into a binding agreement to acquire all 3CL protease biology-related assets owned by NLC Pharma and form a majority-owned subsidiary called 3CL Sciences (“3CL Sciences”). 3CL Sciences will be focused on developing therapeutics, diagnostics and dietary supplements based on the pioneering 3CL protease (3CLpro, Main Protease, Mpro, Nsp5) biology work of Dorit Arad, PhD, who will be appointed Chief Scientific Officer of the new company. We believe this acquisition will solidify Todos Medical’s position as a key player in the development and commercialization of 3CL protease-related products. These products currently include Tollovir®, a therapeutic drug candidate for the treatment of COVID-19 and other nidovirus coronaviruses, TolloTest ™, a diagnostic testing platform to identify the presence of the 3CL protease related to SARS-CoV-2, and Tollovid® & Tollovid Daily™, 3CL protease inhibitor dietary supplements that support and maintain healthy immune function. Additionally, the acquisition gives Todos Medical access to discoveries made by Dr. Arad related to the development and commercialization of new chemical entities targeting the 3CL protease and other mechanisms critical for the treatment of COVID-19 using her ‘mechanism-based design’ approach, as well as new designs for mass-scale deployment of the TolloTest technology.

Key Points: 
  • We believe this acquisition will solidify Todos Medicals position as a key player in the development and commercialization of 3CL protease-related products.
  • Under the terms of the agreement, Todos Medical will own 60% of 3CL Sciences, and the shareholders of NLC Pharma will own 40% upon the execution of definitive agreements (the Closing) to acquire all intellectual property and assets related to 3CL protease biology-related products to which NLC Pharma has rights.
  • Todos Medical will assign its European licensing agreement T-Cell Hellas Protect S.A. to 3CL Sciences.
  • Tollovid's 3CL protease inhibition activity release criteria is at least twice as stringent as Tollovid Daily's 3CL protease inhibition release criteria.

DGAP-News: Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe

Retrieved on: 
Wednesday, November 24, 2021
Synthase, Emergency Use Authorization, European Economic Area, Company, Legislation, Biotechnology, Dietary supplement, Immune system, Cell cycle, COVID, CEO, TMB-2, Pressure, Time, Brain, Lymphocyte, Distribution, Alzheimer's disease, TBIA, Research, T cell, Method, Solution, U.S. Securities and Exchange Commission, OTCQB, Apoptosis, Patient, Neuron, Cancer, Technology, Industry, Monocyte, MERS, Plasma, PCR, Neurodegeneration, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, COVID-19, Knowledge, Pharmaceutical industry, Security (finance), Vaccine, Animal, Medical imaging, Tollovid(R) & Tollovid Daily(TM), Tollovir(R), T-Cell Protect Hellas S.A., Todos Medical Ltd., TOLLOVID(R) & TOLLOVID DAILY(TM), TOLLOVIR(R), T-CELL PROTECT HELLAS S.A., TODOS MEDICAL LTD.

New York, NY, and Tel Aviv, ISRAEL - via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its joint venture partner NLC Pharma, Ltd., today announced that it has entered into an exclusive European licensing & distribution agreement with T-Cell Protect Hellas S.A. (T-Cell Protect or T-Cell) for a product based on its Tollovid(R) and Tollovid Daily(TM) 3CL protease inhibitor and immune support dietary supplements. The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months. T-Cell has placed an initial purchase order for 50,000 bottles of the Tollovid Daily product that is expected to meet the demand of an initial rollout to a subset of the 11,000 stores located throughout Greece. More information about the product can be found at www.tcellprotect.com. Under the terms of the agreement, T-Cell Protect will purchase finished product at wholesale from Todos until such time as T-Cell Protect establishes manufacturing capabilities at a facility it currently operates in Greece to support the European market. At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect. The Company anticipates revenue to be generated from this agreement beginning in the current quarter.

Key Points: 
  • Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe
    The issuer is solely responsible for the content of this announcement.
  • The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.
  • At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect.
  • "We believe this distribution agreement & related investment validates our commercial approach for our Tollovid and Tollovid Daily products," said Gerald E. Commissiong, President & CEO of Todos Medical.

Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid® Products Covering 30 Countries in Europe

Retrieved on: 
Wednesday, November 24, 2021
Biotechnology, Health, Oncology, Medical Devices, Patient, Synthase, Neuron, Apoptosis, TMB-2, CEO, Cancer, Pressure, Emergency Use Authorization, Technology, Time, Industry, MERS, Monocyte, Company, Brain, Lymphocyte, PCR, Plasma, Neurodegeneration, European Economic Area, Severe acute respiratory syndrome coronavirus 2, Solution, Cancer immunotherapy, Alzheimer's disease, COVID-19, TBIA, Legislation, U.S. Securities and Exchange Commission, Medicine, Research, Biotechnology, Dietary supplement, OTCQB, Knowledge, T cell, Immune system, Method, Cell cycle, COVID, Vaccine, Pharmaceutical industry, Animal, Medical imaging, Tollovid® & Tollovid Daily™, Tollovir®, T-Cell Protect Hellas S.A., Todos Medical Ltd., TOLLOVID® & TOLLOVID DAILY™, TOLLOVIR®, T-CELL PROTECT HELLAS S.A., TODOS MEDICAL LTD.

The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.

Key Points: 
  • The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.
  • At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect.
  • The potential for Tollovid and Tollovid Daily in Europe is quite significant and we are excited to bring them to market.
  • We believe this distribution agreement & related investment validates our commercial approach for our Tollovid and Tollovid Daily products, said Gerald E. Commissiong, President & CEO of Todos Medical.

Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece

Retrieved on: 
Monday, November 22, 2021
Synthase, Company, Legislation, Todos, GLOBE, Biotechnology, Immune system, Cell cycle, COVID, CEO, TMB-2, Pressure, Brain, Lymphocyte, Alzheimer's disease, TBIA, Research, T cell, Method, Coronavirus, Partnership, Solution, U.S. Securities and Exchange Commission, OTCQB, Apoptosis, Patient, Neuron, Cancer, US Foods, Technology, Industry, Monocyte, MERS, Plasma, PCR, Neurodegeneration, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, COVID-19, Knowledge, Vaccine, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease biology-focused joint venture partner NLC Pharma, Ltd., today announced it has received an initial purchase order from its European distribution partner T-Cell Protect Hellas S.A. (“T-Cell Protect” or “T-Cell”) for fifty thousand (50,000) bottles of its Tollovid Daily™ dietary supplement formulated product to be marketed under the T-Cell Protect brand (www.tcellprotect.com). The initial 50,000-bottle purchase order is expected to give T-Cell Protect a sufficient amount of product to complete its initial planned roll-out of T-Cell Protect to a subset of its 11,000 store retail distribution network throughout Greece, while also providing T-Cell Protect with sufficient marketing information to evaluate the relative number of maximum strength Tollovid® bottles it will need to purchase to fulfill demand for the Greek market for the first half of 2022. T-Cell Protect is in the process of establishing manufacturing capabilities for Tollovid and Tollovid Daily that will service the European market as part of its related 30 European country license agreement with Todos.

Key Points: 
  • T-Cell Protect is in the process of establishing manufacturing capabilities for Tollovid and Tollovid Daily that will service the European market as part of its related 30 European country license agreement with Todos.
  • Our initial focus is to conduct a targeted launch that aims to optimize marketing for the eight (8) largest countries in Europe before expanding throughout the continent.
  • The potential for Tollovid and Tollovid Daily in Europe is quite significant.
  • Tollovid Daily is a twice daily immune support product that is designed to provide ongoing daily immune support for the person on the go.

Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients

Retrieved on: 
Friday, November 19, 2021
Patient, Synthase, Neuron, Apoptosis, Coronavirus, TMB-2, Cancer, Pressure, Technology, Monocyte, MERS, Brain, Company, Lymphocyte, PCR, Plasma, Neurodegeneration, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, Alzheimer's disease, COVID-19, TBIA, Legislation, U.S. Securities and Exchange Commission, Research, Biotechnology, OTCQB, Knowledge, Immune system, Method, Cell cycle, COVID, Pharmaceutical industry, Medical imaging

New York, NY, and Tel Aviv, ISRAEL, Nov. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease biology-focused joint venture partner NLC Pharma, Ltd., today is very pleased announce an update regarding the ongoing clinical development of Tollovir®, a oral antiviral 3CL protease (3CLpro, Main protease, Mpro, Nsp5) inhibitor & anti-cytokine therapeutic candidate for the treatment of COVID-19. The enrollment of the 77-patient, Phase 2, randomized, double-blind, placebo controlled clinical trial in hospitalized COVID-19 patients has been paused at the two open clinical sites in Israel, Shaare Zedek Medical Center in Jerusalem and Hillel Yaffe Medical Center in Hadera, to allow for an interim analysis of the data. The Company expects data from the interim analysis to be reviewed by the trial Data Safety and Monitoring Board (DSMB) in the fourth quarter of 2021.

Key Points: 
  • Tollovir is a 3CL protease inhibitor and anti-cytokine therapeutic candidate for the treatment of the nidovirus subcategory of coronaviruses that includes SARS-CoV-2, COVID-19, SARS-CoV-1, MERS and 229E.
  • Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti-cytokine activity.
  • Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID-19.
  • Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, long-haul COVID and potentially pediatric COVID-19.

Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe

Retrieved on: 
Thursday, November 18, 2021
Synthase, Emergency Use Authorization, European Economic Area, Company, Legislation, GLOBE, Biotechnology, Dietary supplement, Immune system, Cell cycle, COVID, CEO, TMB-2, Pressure, Time, Â, Brain, Lymphocyte, Alzheimer's disease, TBIA, Research, TEL, T cell, Method, Solution, U.S. Securities and Exchange Commission, OTCQB, Apoptosis, Patient, Neuron, Cancer, Technology, Industry, Monocyte, MERS, Plasma, PCR, Neurodegeneration, Severe acute respiratory syndrome coronavirus 2, Cancer immunotherapy, COVID-19, Knowledge, NEW, Pharmaceutical industry, Medical imaging

The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.

Key Points: 
  • The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months.
  • At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect.
  • The Company anticipates revenue to be generated from this agreement beginning in the current quarter.
  • We believe this distribution agreement & related investment validates our commercial approach for our Tollovid and Tollovid Daily products, said Gerald E. Commissiong, President & CEO of Todos Medical.

Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe

Retrieved on: 
Tuesday, November 16, 2021
Quality of life, Breast, Lung cancer, Cancer, Spectra, TNBC, Plasma, Cancer immunotherapy, Cytokine, SAN, CEO, Immune system, Technology, Blood, Love, CE, Growth, Immunotherapy, Software, Intention, Breast cancer, Woman, Horizon Fuel Cell Technologies, Local development framework, Toxicity, Patient, Renewable energy, Pharmaceutical industry, Medical imaging

The agreement will help advance a cancer therapy that selectively removes immune inhibitors from a patient's bloodstream.

Key Points: 
  • The agreement will help advance a cancer therapy that selectively removes immune inhibitors from a patient's bloodstream.
  • The agreement will result in the combination of Terumo Blood and Cell Technologies' industry-leading Spectra OptiaApheresis System with Immunicom's CE marked immuno-oncology LW-02 Column, for application to patients with advanced refractory triple negative breast cancer (TNBC).
  • In addition, under the agreement, Terumo Blood and Cell Technologies will be the exclusive distributor in Germany, France, Italy, and Spain with potential for future geographic expansion.
  • The treated plasma is recombined with the rest of the blood and then returned to the patient.